VBL Therapeutics

VBL Therapeutics is a late-stage clinical biopharmaceutical company focused on the development of cancer treatments. VBL's clinical pipeline is based on two proprietary platforms that leverage the body's natural physiologic and genetic regulatory elements. VBL has developed an oncology program and an anti-inflammatory program based on these platforms.
The company's lead candidate, VB-111, is a gene-based biologic for recurrent glioblastoma (rGBM). Phase 2 interim data show an overall survival benefit for VB-111 in rGBM, providing proof-of-concept, with a high level of safety and tolerability. VB-111 has received orphan drug designation in the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with rGBM. VBL Therapeutics plans to begin Phase 3 clinical trial of VB-111 in rGBM under a special protocol assessment agreement granted by the FDA.
VBL's oncology program is based on its proprietary Vascular Targeting System platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. VBL has also developed a proprietary platform of small molecules, Lecinoxoids, for the treatment of chronic immune-related indications.

Primary Sector

Products

Geographic markets

Anchiano Therapeutics

Targeted Cancer Therapies Based on H19 Gene

Purple Biotech

Tumor-immune Evasion and Drug Resistance Therapies

Nextage Therapeutics

Cannabinoid-based Products for Pharmaceutical Use

Galmed Pharmaceuticals

Oral Therapy for Treatment of Liver Disorders

Intec Pharma

Controlled Drug-delivery Technology for the Upper Gastrointestinal Tract

And much more...